esults of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. March 17. Presented at: American College of Cardiology 2017 Scientific Session in Washington, D.C. Copyright C' 2017 American Medical Communications. All rights reserved. Our mailing address is: American Medical Communicatio

esults of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. March 17. Presented at: American College of Cardiology 2017 Scientific Session in Washington, D.C. Copyright @ 2017 American Medical Communications. All rights reserved. Our mailing address is: American Medical Communication

esults of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. March 17. Presented at: American College of Cardiology 2017 Scientific Session in Washington, D.C. Copyright O 2017 American Medical Communications. All rights reserved. Our mailing address is: American Medical Communication